Best GLP-1 on OptumRx Formulary: 2026 Coverage Matrix

The best GLP-1 on OptumRx formulary depends on why you’re taking it. For weight loss, the Zepbound pen and Wegovy are the two covered medications to check first; for type 2 diabetes, the lane is Ozempic, Mounjaro, Rybelsus, and Trulicity. The most important rule: being listed on the formulary does not guarantee approval, because prior authorization rules, your plan’s benefit design, your diagnosis, and even the drug’s form still decide it.

OptumRx itself says tier costs are “set by your employer or plan sponsor,” and that “where differences exist between this list and your benefit plan, the benefit plan documents rule.”

So instead of a fake universal pick, we match the medication to your situation, then show you how to confirm it. Think of the rest of this page as turning insurance language into a plan you can actually act on.

On both the OptumRx Select Standard and Premium 2026 formularies we reviewed, Wegovy, the Zepbound pen, Saxenda, and Qsymia appear in the weight-management area as Tier 2 (a mid-range preferred-brand cost level), each requiring prior authorization and the “benefit design” flag. In the diabetes section, Ozempic, Mounjaro, Rybelsus, and Trulicity are Tier 2 with prior authorization and quantity limits.

One detail jumps out: on the Premium formulary, the Zepbound single-dose vial is excluded, while the pen is covered at Tier 2. Same medicine, different form, different answer.

A drug can be on the formulary and still be denied because of prior authorization rules, your plan’s benefit design, a diagnosis mismatch, a quantity limit, or the wrong drug form. The smart question isn’t “is it on the list?” — it’s “is it covered for my reason, my form, and my plan?”

Prior authorization (PA) means your doctor has to send OptumRx more information before the drug is covered. Quantity limit (QL) means the plan caps how much you get at a time. Step therapy (ST) means you may have to try a cheaper option first. Benefit design means your employer decides whether it’s covered at all. None of these are dead ends — they’re hurdles with clear rules.

If your plan covers both and your doctor agrees either is appropriate, the Zepbound pen is usually the first formulary check for weight-loss-only or sleep-apnea cases, and Wegovy is the first check when you have known heart disease that may qualify you under its heart-risk approval. This is a coverage-and-diagnosis decision, not a medical ranking — your clinician decides what’s right for your body.

When to ask about Zepbound first

Zepbound (tirzepatide) is FDA-approved to help adults with obesity, or overweight plus a weight-related condition, lose weight and keep it off. In its main trial, participants lost up to about 21% of their body weight on the highest dose over 72 weeks. It’s also FDA-approved for moderate-to-severe sleep apnea in adults with obesity — a real coverage advantage if your plan won’t cover plain “weight loss” but will cover a sleep-apnea diagnosis. Just remember the pen-versus-vial catch.

When Wegovy is the stronger coverage conversation

Wegovy (semaglutide) is approved for the same weight purpose, with about 15% average weight loss in its main trial. It’s also FDA-approved to reduce the risk of major cardiovascular events — heart attack and stroke — in adults with known heart disease and obesity or overweight. That second approval can open a coverage door if your plan excludes weight-loss drugs but will cover heart-risk reduction.

Where Saxenda fits

Saxenda (liraglutide) is the older, daily-shot option. It’s not most people’s first pick, but because it’s covered (Tier 2) on these formularies, it can matter if your plan prefers it or uses it as a fallback.

A line we won’t cross:

Ozempic and Mounjaro are diabetes drugs. Please don’t try to get a diabetes drug approved as a weight-loss workaround. It’s the wrong diagnosis lane, it tends to get denied, and it muddies your record. Match the drug to the real reason.

For type 2 diabetes, OptumRx’s 2026 formularies list Ozempic, Mounjaro, Rybelsus, and Trulicity as Tier 2 (preferred), each with prior authorization and quantity limits. Which one is “best” depends on your A1c, your heart and kidney history, your other medications, side effects, and your plan’s rules — your doctor weighs all of that.

• Ozempic (semaglutide) — a weekly shot for type 2 diabetes, with added FDA-approved uses for certain heart and kidney risks in adults with diabetes.
• Mounjaro (tirzepatide) — a weekly shot for type 2 diabetes. This is the diabetes-labeled tirzepatide, not the weight-loss one.
• Rybelsus (semaglutide) — the daily pill for diabetes. Note: Rybelsus and the Wegovy weight-loss pill are not interchangeable, and the FDA says oral semaglutide products aren’t swapped milligram-for-milligram.
• Trulicity (dulaglutide) — a well-established weekly diabetes shot.

Diabetes coverage is usually easier to get than weight-loss coverage, because these are prescribed for an on-label condition your plan already covers. In Ro’s 2025 coverage-checker report, nearly all users had coverage for a diabetes GLP-1, versus about 43% for weight loss. See our best GLP-1 for type 2 diabetes guide.

Foundayo (orforglipron) is Eli Lilly’s once-daily weight-loss pill, FDA-approved on April 1, 2026. The Wegovy pill (oral semaglutide) was FDA-approved December 22, 2025. Both are real and FDA-approved, but because they’re so new, neither Foundayo nor the oral Wegovy tablet appeared in the Select Standard or Premium PDFs we checked — so don’t assume coverage yet. Search your exact plan.

A few specifics worth knowing while coverage catches up:

• Through Ro, Foundayo is listed at $149 the first month, then $199–$299 (same as LillyDirect). Eligible people with commercial insurance may pay as little as $25/month with Lilly’s savings card, and eligible Medicare Part D members may get Foundayo for about $50/month starting July 1, 2026 through the Medicare GLP-1 Bridge.
• The Wegovy pill is a weight-loss form of semaglutide — different from Rybelsus, which is the diabetes pill. If you want a pill specifically, ask your doctor which makes sense and search both by exact name in your portal.

We’ll keep this section updated as plans add these — it’s exactly the kind of thing that changes month to month. See our full OptumRx Foundayo coverage guide.

Log into your OptumRx account or app, search each drug by its exact name and form, look for PA, QL, step therapy, or “excluded” notes, and save screenshots before your appointment. Five minutes here can save you weeks.

A strong prior authorization matches the drug’s FDA-approved use and your plan’s exact criteria. For weight-loss drugs that usually means your BMI, any related conditions, and prior attempts; for Wegovy’s heart pathway it means documented heart disease; for Zepbound’s sleep-apnea pathway it means a moderate-to-severe OSA diagnosis; for diabetes drugs it means clear type 2 diabetes documentation.

Don’t switch medications blindly. Get the denial reason in writing first, then match your next step to the reason. Most denials are fixable, and you generally have a window to appeal.

If your plan flat-out excludes weight-loss drugs, appealing a benefit exclusion rarely works mid-year, but you still have real choices:

• Self-pay on the brand you wanted. See the cash-pay prices in the next section. Ro lists the same medication prices as LillyDirect and NovoCare.
• A different provider or pricing. Sesame Care lets you choose a clinician and shows cash-pay branded prices.
• Medicare members: A new Medicare GLP-1 Bridge starts July 1, 2026 for eligible Medicare Part D members. It offers Wegovy, the Zepbound KwikPen, and Foundayo for a $50 monthly copay — running outside the normal Part D benefit, so that $50 doesn’t count toward your deductible or out-of-pocket maximum.

If your plan won’t cover a GLP-1, cash-pay prices in 2026 depend heavily on the drug, form, and dose — pills start lower than pens. Here are current examples through Ro, which lists the same medication prices as LillyDirect and NovoCare. The membership is billed separately, and prices rise at higher doses.

Ro fits when you want FDA-approved GLP-1 access plus someone to handle the insurance check and prior authorization for you. Sesame Care fits when you want to choose your own clinician or need a cash-pay branded option if your plan excludes coverage.

One honest thing before you click

Ro isn’t free, and the pricing trips people up. The Ro Body membership is $39 to start, then as low as $74/month on an annual plan (or $149/month month-to-month) — and that fee covers your visits, ongoing care, any lab work ordered, and the insurance team, not the medicine, which is billed separately. Since Ro lists the same medication prices as LillyDirect and NovoCare, if all you want is the lowest cash price and you’re happy to do the prior-authorization legwork yourself, going direct lets you skip the membership fee — that’s a fair call. But if you’ve got OptumRx and you want someone to fight the prior-authorization battle for you — check your plan, file the paperwork, refile if you’re denied — that’s exactly what Ro was built for.